Rona Ortenberg

Rona Ortenberg

Auto-generated profile, based on publicly available information

Rona Ortenberg

The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Science
Verified
Journal Article
Closed access
PDF file
EBErez N. Baruch
Erez N. Baruch
IYIlan Youngster
Ilan Youngster
GBGuy Ben-Betzalel
Guy Ben-Betzalel
RORona Ortenberg
Rona Ortenberg
ALAdi Lahat
Adi Lahat
BBBen Boursi
Ben Boursi
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573